Latest News
Quidel Announces the Availability of Triage® PLGF Assay for Use with Quidel’s Triage® MeterPro Instrumented System
SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2018--
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a
provider of rapid diagnostic testing solutions, cellular-based virology
assays and molecular diagnostic systems, announced today that the
manufacturing of Quidel Triage® PLGF Test is set to resume in
2019 and be commercially available outside the US for clinical use in Q1
2019. Knowledge of maternal circulating concentration of Placental
Growth Factor (PLGF), a biomarker for placental dysfunction, aids in the
early and accurate diagnosis of preterm pre-eclampsia and helps
clinicians to accurately risk-stratify pregnant women resulting in more
efficient use of healthcare resources and the potential for cost-saving
to the healthcare system.
Careers
Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.
Support
To place orders, get assistance with shipments, pricing or contract administration view our Customer Support page.
Visit our Technical Support page to get help with product specifications, supporting docs or general support issues.
NEW: Register at MyQuidel.com to download and install the latest Software Updates, Assay and testing capabilities for your Quidel Instruments.